#Australia #Melbourne #4DMedical #CT:VQ™ #TGA Approval

4DMedical's Revolutionary CT:VQ™ Approved in Australia

In a significant advancement for respiratory health diagnostics, 4DMedical Limited (ASX: 4DX), a pioneer in advanced imaging technology, has announced the Therapeutic Goods Administration (TGA) approval for its innovative CT:VQ™ technology. This regulatory nod represents a leap forward in the realm of non-contrast ventilation-perfusion imaging and will facilitate its commercial deployment throughout Australia.

What is CT:VQ™?

CT:VQ™ is a state-of-the-art imaging solution that enables healthcare professionals to obtain essential ventilation and perfusion data directly derived from routine chest CT scans, eliminating the need for injected contrast agents, radiotracers, or specialized nuclear medicine infrastructure. This technology is poised to transform how lung function assessments are conducted across various healthcare settings.

Andreas Fouras, the founder and CEO of 4DMedical, expressed his enthusiasm regarding this achievement, stating, "The TGA approval marks a pivotal milestone for respiratory diagnostics in our market. As the first and only non-contrast CT-based ventilation-perfusion imaging solution, CT:VQ™ offers healthcare practitioners detailed functional insights into lung performance without the requirement for additional specialized equipment."

Advantages Over Traditional Methods

Traditionally, ventilation-perfusion imaging relied on nuclear medicine facilities, requiring specific equipment and the use of radioactive materials. In contrast, CT:VQ™ provides an efficient software-based alternative that integrates with existing standard CT imaging systems, enhancing accessibility for lung functional assessments in diverse clinical environments, whether metropolitan, regional, or rural.

This capability is particularly beneficial for medical centers lacking in-house nuclear medicine services, allowing them to conduct necessary lung evaluations while conserving the resources typically reserved for therapeutic and diagnostic nuclear medicine applications.

As healthcare systems worldwide increasingly seek scalable and cost-effective technological solutions, the CT:VQ™ system is emerging as a practical answer, leveraging existing CT imaging infrastructure to broaden the reach of functional lung imaging. This innovation not only streamlines workflows but also augments the capacity of healthcare providers to deliver personalized patient care.

Global Context

Since receiving FDA approval in 2025, CT:VQ™ has demonstrated its utility in several leading US healthcare institutions, including Stanford, Cleveland Clinic, and University of Miami, showcasing its effectiveness in enhancing clinical outcomes through improved diagnostic precision. The recent approval from Australia positions this unique technology for further growth and adaptation in international markets, addressing the burgeoning demand for advanced medical imaging solutions.

4DMedical aims to redefine the landscape of respiratory disease management by integrating advanced imaging technologies with innovative artificial intelligence capabilities. With a growing software portfolio that now includes CT LVAS™ and the FDA-approved XV LVAS® for lung ventilation analysis, 4DMedical is setting new standards in cardiothoracic imaging.

Conclusion

The approval of CT:VQ™ in Australia heralds a new chapter for lung function assessment, allowing healthcare professionals to access critical imaging data without the complexities tied to traditional methods. By capitalizing on already available resources, CT:VQ™ has the potential to revolutionize patient diagnostics and monitoring, making it an invaluable tool for practitioners in Australia and beyond.

As healthcare continues to evolve, innovations like CT:VQ™ are vital in shaping the future of medical imaging technologies. The journey to implement this cutting-edge technology throughout Australian healthcare systems underscores a commitment to improving patient outcomes and expanding access to essential respiratory assessments.